PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial

Authors

Institutions

Publication Details

Journal
Cancer Cell International
Published
2025-02-08
DOI
https://doi.org/10.1186/s12935-025-03669-2
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial

Zusheng Xu, Peng Sun, Hong Cen, Xuekui Gu et al.
1 citations
Cancer Cell International
Lymphoma Diagnosis and Treatment
1.47
article

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial

Zusheng Xu, Peng Sun, Hong Cen, Xuekui Gu, Hanying Bao, Zhen Cai, Zuhong Xu, Haiyan Yang, Zhi-Ming Li, Rui Huang
article en
1 citations

Abstract

No abstract available for this paper.
Cancer Cell InternationalVol. 25(1)
Sun Yat-sen University (CN), Zhejiang Cancer Hospital (CN), First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN), Zhujiang Hospital (CN), Sun Yat-sen University Cancer Center (CN), Tumor Hospital of Guangxi Medical University (CN), First Affiliated Hospital Zhejiang University (CN), Southern Medical University (CN)
National Natural Science Foundation of China, Sun Yat-sen University, National Science and Technology Major Project, Guangzhou Science and Technology Program key projects, Sun Yat-sen University Cancer Center
Openalex Percentile: Top 23%
Lymphoma Diagnosis and Treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial — Zusheng Xu, Peng Sun, et al. · Cancer Cell International (2025) | TGRS Research Map | TGRS